Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate

Japanese Journal of Clinical Oncology

Volumn 36, Issue 1, 2006, Pages 17-24

  Ryu, Min Hee ^a   Lee, Jae Lyun ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Kang, Hye Jin ^a   Sohn, Hee Jung ^a   Lee, Jung Shin ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Disease progression; Gastrointestinal stromal tumor; Imatinib; Prognosis; Sarcoma; Spiral computed; Tomography

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DECISION MAKING; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; PYRIMIDINES; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 32244444918     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi212     Document Type: Article

References (18)

1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80.
2. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(Suppl 5):S83-7.
3. Verweij J, Casali PG, Zaleberg PJ, LeCesne A, Reichardt P, Blay J-Y, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-34.
4. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-11.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
7. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10:3076-81.
8. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
9. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CDM, Tuncali K, et al. Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. Proc Am Soc Clin Oncol 2004;23: 197(abstract 3010).
10. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
11. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002;179: 1059-62.
12. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64.
13. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578-82.
14. Benjamin RS, Choi H, Charnsangavej C, Macapinlac H, Burgess MA, Chen L, L, et al. We should desist using RECIST, at least in GIST. Program of the Connective Tissue Oncology Society 9th Annual Scientific Meeting 2003;40 (abstract 195).
15. Choi H, Charnsangavej C, Faria SdC, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183: 1619-28.
16. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 2003;39:2012-20.
17. Chen LL. Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-9.
18. Fletcher JA, Corless CL, Dimitrijevic S, Von Mehren M, Eisenberg B, Joensuu H, et al. Mechanisms of resistance to imatinib mesylate(IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003;22:815 (abstract 3275).